Meptazinol

Summary

Meptazinol (CHEMBL314437) is an approved small molecule (ATC N02AX05); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N02AX05
• Indications: 1 condition
• Chemistry: 233.35 Da · C15H23NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL314437
Name	Meptazinol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	41049
ATC	N02AX05
Molecular formula	C15H23NO
Molecular weight	233.35
InChIKey	JLICHNCFTLFZJN-UHFFFAOYSA-N

SMILES: CCC1(CCCCN(C1)C)C2=CC(=CC=C2)O

IUPAC name: 3-(3-ethyl-1-methylazepan-3-yl)phenol

Also known as: IL-22811, Meptazinol, MEPTAZINOL, meptazinol

Parent form; salt/anhydrous children: CHEMBL1477274

Patent coverage: 2,146 distinct patent families (9,683 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Muscarinic acetylcholine receptor M2, Acetylcholinesterase, Sodium-dependent serotonin transporter, Mu-type opioid receptor, Cholinesterase, Acetylcholinesterase, Solute carrier family 22 member 1.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
OPRM1	7.5	Ki	32	nM	CHEMBL_ACT_27066992
OPRM1	7.5	Ki	32	nM	CHEMBL_ACT_27465338
OPRM1	7.5	Ki	32	nM	CHEMBL_ACT_28072715
OPRM1	7.5	Ki	32	nM	CHEMBL_ACT_28876652
OPRM1	7.08	AC50	82.6	nM	CHEMBL_ACT_25158641
ACHE	5.26	AC50	5511	nM	CHEMBL_ACT_25143014

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).